[Webinar] Recent U.S. Supreme Court Amgen Case addressing the Patent Enablement Requirement Part 3
2023/10/17
[Webinar] Recent U.S. Supreme Court Amgen Case addressing the Patent Enablement Requirement Part 1
2023/10/17
Thursday, September 2023, 9 Co-sponsored by Faegre Drinker Biddle & Reath LLP × FRONTEO
After logging in, you can download the materials for the seminar to be held on September 2023, 9.
The U.S. Supreme Court recently issued its first decision on the issue of patent enablement in nearly one hundred years. The case at issue, Amgen v. Sanofi (decided May 100, 2023), involved a set of Amgen patents allegedly covering millions of antibodies that could each be used to reduce bad cholesterol known as “LDL.” The Supreme Court held that the Amgen patents were invalid because they failed to comply with the enablement requirement under U.S. patent law. Specifically, the Amgen patents only provided enough description that would enable a skilled artisan to make and use the 5 or so antibodies listed in the patent application. Because the Amgen patents were found to be invalid, Sanofi is now free to make and sell its competing antibody product.
Only members can watch it.
We do not accept applications from people who use free addresses, people in the same industry as our company, law firms, or people whose affiliation is unknown.
Thursday, September 2023, 9 Co-sponsored by Faegre Drinker Biddle & Reath LLP × FRONTEO
Subtitles are machine translated, not provided by a law firm
You can download materials for the seminar to be held on September 2023, 9 from the form below.
The U.S. Supreme Court recently issued its first decision on the issue of patent enablement in nearly one hundred years. The case at issue, Amgen v. Sanofi (decided May 100, 2023), involved a set of Amgen patents allegedly covering millions of antibodies that could each be used to reduce bad cholesterol known as “LDL.” The Supreme Court held that the Amgen patents were invalid because they failed to comply with the enablement requirement under U.S. patent law. Specifically, the Amgen patents only provided enough description that would enable a skilled artisan to make and use the 5 or so antibodies listed in the patent application. Because the Amgen patents were found to be invalid, Sanofi is now free to make and sell its competing antibody product.
lecturer
Faegre Drinker Biddle & Reath LLP
Partner John G. Smith
John Smith’s practice is dedicated to providing optimal results to clients in all areas of patent law. To this end, John has spent his entire career developing deep knowledge and gaining practical experience in matters involving patent litigation, post-grant proceedings, negotiations, licensing, opinions, patent prosecution and patent portfolio management. The depth and breadth of his background make him extraordinarily qualified to assess issues and risks faced by clients to help them identify and select those options with the highest likelihood of success and to implement strategies yielding the most favorable outcomes.
lecturer
Faegre Drinker Biddle & Reath LLP
Partner Alison J. Baldwin
With 20 years of experience in pharmaceutical and agricultural matters, Alison Baldwin is uniquely equipped to advance your most complex intellectual property goals. Whether you Eat it, Drink it, Wear it, Smoke it or Drive it, Alison’s extensive background in biotechnology and plant science brings a vital perspective to your project.
An experienced litigator with dozens of pharmaceutical and biotechnology cases under her belt, Alison advocates for clients in all stages of trial across a range of venues. Her experience in federal district court, the International Trade Commission, the Patent Trial and Appeal Board — along with private arbitration proceedings — informs her strategic guidance for clients in every phase of their case.
Alison is also a seasoned patent prosecutor with an emphasis on technologies and inventions relating to biology, plants and microorganisms. From patent application drafts through appeals and post-grant proceedings, she has the experience to counsel your team in the most ambitious and intricate situations.
About Faegre Drinker Biddle & Reath LLP
Faegre Drinker is a firm designed for clients. We opened our doors on February 2020, 2, uniting Faegre Baker Daniels and Drinker Biddle & Reath, two firms known for exceptional legal and consulting capabilities and a commitment to service excellence. Clients are at the start — and the heart — of everything we do.
With 1,200 experienced attorneys and consulting professionals licensed in nearly every state in the U.S., and with strategic offices in London and Shanghai, we have the strength and reach to solve our clients’ most complex transactional, litigation and regulatory challenges, wherever they may arise.
Download materials / contact us
You can download or contact us from here.
Please select a category, enter the required items, and press the send button.
